ERBB2 and neoplasm: Type II EC is often associated with specific histological subtypes (such as serous and clear cell carcinomas) and molecular markers such as TP53 mutations, HER2/neu amplification, and PI3K/AKT/mTOR pathway alterations, which are linked to aggressive tumor behavior, poorer prognosis, and limited hormonal responsiveness.